Regenative Labs and AAPC announced a strategic healthcare compliance collaboration. By combining AAPC’s medical training and credentialing expertise with Regenative Labs’ human tissue allografts, together both organizations will support the pioneering of the first Wharton’s jelly allografts to be approved for application directly to a defect using a syringe.
[Regenative Labs (Cision US, Inc.)]
